The endothelium, a cellular monolayer lining the blood vessel wall, plays a critical role in
maintaining multiorgan health and homeostasis. Endothelial functions in health include …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐
lowering agents, have been shown to reduce heart failure hospitalizations in patients with …

Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure and a reduced ejection fraction, with or without …

Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have recently been recommended as a
foundational therapy for patients with heart failure (HF) and reduced ejection fraction …

Importance Clinical guidelines for patients with heart failure with reduced ejection fraction
(HFrEF) strongly recommend treatment with a sodium-glucose cotransporter-2 inhibitor …

Aims Sodium–glucose co‐transporter 2 (SGLT2) inhibitors improve clinical outcome in
patients with heart failure (HF), but the mechanisms behind their beneficial effects are not yet …

Aim This review aims to summarize and discuss some of the most relevant clinical trials in
epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021. Data …

Objectives The purpose of this study was to assess the efficacy and safety of dapagliflozin in
patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in …

Arterial hypertension is a leading cause of death globally. Due to ageing, the rising
incidence of obesity, and socioeconomic and environmental changes, its incidence …